• Shanghai Fudan-Zhangjiang posted net profit of RMB 36.78 million, more than doubled from a year earlier on lower R&D spending.
• Revenue fell 4.58% to RMB 372.23 million, while profit before tax climbed to RMB 36.78 million from RMB 5.62 million.
• EBITDA rose to RMB 74.49 million from RMB 47.73 million; net profit margin widened to 10% from 1%.
• Royalty income included a RMB 45 million upfront payment from Fosun Yaohong for overseas rights to Trop2-SN38 ADC.
• Cash and cash equivalents increased to RMB 1.22 billion; operating cash flow rose 32.81% to RMB 82.63 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304493), on August 28, 2026, and is solely responsible for the information contained therein.